Literature DB >> 15014661

Treatment of Delirium With Quetiapine.

Thomas L. Schwartz1, Prakash S. Masand.   

Abstract

INTRODUCTION: Delirium, an organic psychiatric syndrome, occurs in 10% of hospitalized patients and is characterized by fluctuating consciousness and impaired cognition, perception, and behavior.
METHOD: Charts of 11 consecutive patients with delirium were retrospectively reviewed. These patients were given quetiapine fumarate, a novel antipsychotic, as first-line treatment for their symptoms. The charts of a control group of 11 patients treated with haloperidol, the standard treatment for delirium, during the same time period were also evaluated. The Delirium Rating Scale (DRS) was used to evaluate the efficacy of each treatment.
RESULTS: Ten of 11 patients in both groups had > 50% improvement in DRS scores. There was no difference in onset of symptom resolution, duration of treatment, and overall clinical improvement. Quetiapine was better tolerated in these medically ill patients.
CONCLUSION: Quetiapine appears to be an efficacious and well-tolerated treatment for delirium. Further prospective studies are warranted.

Entities:  

Year:  2000        PMID: 15014661      PMCID: PMC181102          DOI: 10.4088/pcc.v02n0103

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  10 in total

1.  Practice guideline for the treatment of patients with delirium. American Psychiatric Association.

Authors: 
Journal:  Am J Psychiatry       Date:  1999-05       Impact factor: 18.112

2.  Delirium in elderly patients treated with risperidone: a report of three cases.

Authors:  R Ravona-Springer; O T Dolberg; S Hirschmann; L Grunhaus
Journal:  J Clin Psychopharmacol       Date:  1998-04       Impact factor: 3.153

3.  A symptom rating scale for delirium.

Authors:  P T Trzepacz; R W Baker; J Greenhouse
Journal:  Psychiatry Res       Date:  1988-01       Impact factor: 3.222

4.  Excess mortality in general hospital patients with delirium: a 5-year follow-up of 519 patients seen in psychiatric consultation.

Authors:  A M van Hemert; R C van der Mast; M W Hengeveld; M Vorstenbosch
Journal:  J Psychosom Res       Date:  1994-05       Impact factor: 3.006

5.  Delirium and other organic mental disorders in a general hospital.

Authors:  P T Trzepacz; G B Teague; Z J Lipowski
Journal:  Gen Hosp Psychiatry       Date:  1985-04       Impact factor: 3.238

6.  The mortality of delirium: an underappreciated problem?

Authors:  W W Weddington
Journal:  Psychosomatics       Date:  1982-12       Impact factor: 2.386

7.  Delirium (acute confusional states).

Authors:  Z J Lipowski
Journal:  JAMA       Date:  1987-10-02       Impact factor: 56.272

8.  Use of high-dose intravenous haloperidol in the treatment of agitated cardiac patients.

Authors:  G E Tesar; G B Murray; N H Cassem
Journal:  J Clin Psychopharmacol       Date:  1985-12       Impact factor: 3.153

9.  Delirium in terminally ill cancer patients.

Authors:  M J Massie; J Holland; E Glass
Journal:  Am J Psychiatry       Date:  1983-08       Impact factor: 18.112

10.  Olanzapine in the treatment of delirium.

Authors:  A Sipahimalani; P S Masand
Journal:  Psychosomatics       Date:  1998 Sep-Oct       Impact factor: 2.386

  10 in total
  9 in total

Review 1.  Clinical pharmacology of old age syndromes.

Authors:  C Broadhurst; K C M Wilson; M T Kinirons; A Wagg; J K Dhesi
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

Review 2.  Delirium: where do we stand?

Authors:  Chi-Un Pae; David M Marks; Changsu Han; Ashwin A Patkar; Prakash Masand
Journal:  Curr Psychiatry Rep       Date:  2008-06       Impact factor: 5.285

3.  Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case.

Authors:  Carla Meyer-Massetti; Simone Vaerini; Alexandra E Rätz Bravo; Christoph R Meier; B Joseph Guglielmo
Journal:  Int J Clin Pharm       Date:  2011-08-02

4.  Delirium: underrecognized and undertreated.

Authors:  Chi-Un Pae; David M Marks; Changsu Han; Ashwin A Patkar; Prakash Masand
Journal:  Curr Treat Options Neurol       Date:  2008-09       Impact factor: 3.598

5.  Novel Antipsychotics in the Treatment of Behavioral Disturbances and Psychoses Associated With Neurodegenerative Disorders.

Authors:  Prakash S. Masand
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-06

6.  Delirium and antipsychotics: a systematic review of epidemiology and somatic treatment options.

Authors:  Joseph D Markowitz; Meera Narasimhan
Journal:  Psychiatry (Edgmont)       Date:  2008-10

7.  Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium.

Authors:  Hyung-Jun Yoon; Kyoung-Min Park; Won-Jung Choi; Soo-Hee Choi; Jin-Young Park; Jae-Jin Kim; Jeong-Ho Seok
Journal:  BMC Psychiatry       Date:  2013-09-30       Impact factor: 3.630

8.  Comparative effectiveness of quetiapine and haloperidol in delirium: A single blind randomized controlled study.

Authors:  Sandeep Grover; Sudhir Mahajan; Subho Chakrabarti; Ajit Avasthi
Journal:  World J Psychiatry       Date:  2016-09-22

9.  A research study review of effectiveness of treatments for psychiatric conditions common to end-stage cancer patients: needs assessment for future research and an impassioned plea.

Authors:  Ralph J Johnson
Journal:  BMC Psychiatry       Date:  2018-04-03       Impact factor: 3.630

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.